- Home
- NMIH vs SUPN Comparison
NMIH vs SUPN Comparison
Compare NMIH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | SUPN |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2013 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NMIH | SUPN |
|---|---|---|
| Price | $41.92 | $47.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $43.25 | ★ $61.60 |
| AVG Volume (30 Days) | 591.0K | ★ 916.2K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $706,440,000.00 | $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | $4.34 | $19.14 |
| P/E Ratio | $32.70 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $34.84 | $32.51 |
| 52 Week High | $43.36 | $59.68 |
Technical Indicators
Market Signals| Indicator | NMIH | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 52.64 |
| Support Level | $36.61 | $47.31 |
| Resistance Level | $42.15 | $52.24 |
| Average True Range (ATR) | 0.93 | 1.64 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 54.05 | 31.60 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.